Home > Healthcare > Medical Devices > Diagnostic Devices > U.S. Direct-to-Consumer Genetic Testing Market

U.S. Direct-to-Consumer Genetic Testing Market Share

  • Report ID: GMI4368
  • Published Date: Jan 2023
  • Report Format: PDF

U.S. Direct-to-Consumer Genetic Testing Market Share

Some leading U.S. DTC genetic testing market players include

  • Ancestry
  • Easy DNA
  • 23andMe, Inc.
  • HomeDNA
  • Counsyl
  • Living DNA Ltd.
  • Pathway genomics

Many of these companies are focusing on product innovations to keep ahead of the competition. For example, in January 2022, 23andMe, a consumer genetics and research firm, received FDA approval for its DTC genetic test on a hereditary prostate cancer marker. This strategic move will help the company enhance its position in the market landscape.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The U.S. market for DTC genetic testing was valued at over USD 1.5 billion in 2022 and is anticipated to grow at over 11% CAGR from 2023 to 2032., driven by rising cases of genetic disorders in the country.

Predictive testing segment is slated to grow at over 13% CAGR from 2023 to 2032, fueled by increasing occurrences of inherited disorders.

SNP chips segment is anticipated to grow at over 11.5% CAGR from 2023 to 2032, fueled by the rising use of SNP chips to determine the genome sequence and improve the efficiency of the tests.

Some major U.S. direct-to-consumer genetic testing market contenders include MyHeritage, Blueprint Genetics Oy, Ambry Genetics, DNA Genotek Inc, and Dante Lab, among others.

U.S. Direct-to-Consumer Genetic Testing Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 20
  • Tables & Figures: 66
  • Countries covered: 1
  • Pages: 60
 Download Free Sample